Continuous Glucose Monitoring: A Case Study for Commercializing Products In The Era of Patient-Driven Health Care
Continuous glucose monitoring for patients with diabetes presents an example of how an individual product has far less value than the integrated solution the technology enables. While continuous glucose monitoring offers significant value to a broad range of patients, the technology has still not fulfilled its market potential. Factors hindering more widespread adoption include inaccuracy, difficulty in using the systems, and low levels of patient adherence. But the greatest obstacle in CGM is the disconnect between CGM and treatment planning; CGM produces mounds of data that patients and even physicians don't know how to use. According to Health Care Advances, if this powerful dataset is optimized, shared, and applied, it could shift CGM from a niche product for a small number of type 1 diabetes patients into a standard of care for many metabolic diseases.
Marie Schiller, Sheela Hegde, and Brittany Birrell Carroll
Continuous glucose monitoring has yet to achieve its full potential. Over the five years that continuous glucose monitoring (CGM) has...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.